GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Within recent years, glucagon-like peptide 1 receptor agonists (GLP-1-RA) have emerged as a new treatment option for type 2 diabetes. The GLP-1-RA are administered subcutaneously and differ substantially in pharmacokinetic profiles. AREAS COVERED: This review describes the pharmacokinetics and safety aspects of the currently available GLP-1 receptor agonists, liraglutide (based on the structure of native GLP-1), exenatide twice daily and exenatide once weekly (based on exendin-4) in relation to the kinetics and toxicology of native GLP-1. The review is based on electronic literature searches and legal documents in the form of assessment reports from the European Medicines Agency and the United States Food and Drug Administration. EXPERT OPINION: GLP-1-based therapy combines several unique mechanisms of action and have the potential to gain widespread use in the fight against diabetes and obesity. The difference in chemical structure have strong implications for key pharmacokinetic parameters such as absorption and clearance, and eventually the safety and efficacy of the individual GLP-1-RA. The main safety concerns are pancreatitis and neoplasms, for which there are no identifiable differences in risk between the available agents. Antibody formation and injection site reactions are more frequent with the exendin-4-based compounds. The efficacy with regard to Hb(A1c) reduction is superior with the longer-acting agonists, whereas the shorter-acting GLP-1-RA seems to provide greater postprandial glucose control and lower tolerability as a possible consequence of less induction of tachyphylaxis. The future place of these agents will depend on the added safety and efficacy data in the several ongoing cardiovascular outcome trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., Macchiarulo, A., Yamamoto, H., Mataki, C., Pruzanski, M., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.08.001 · Cited by 1,885 · cited 1×
“Most notably, there are specific receptors for several hormones, neurotransmitters, free fatty acids of various length [10] and bile acids [11].”
BackgroundBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 3×
“Thus, superior efficacy (toward FPG and HbA1c) and tolerability has been demonstrated with compound showing stable plasma residence compared to compounds with a more intermittent plasma residence [64,79].”
BackgroundZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124 · cited 1×
“DPP-4 cleaves off the two N-terminal amino acids of peptides with a penultimate proline or alanine residue, which in the case of GLP-1 abolishes the insulinotropic activity [23,24].”
BackgroundDrucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 9×
“However, it is important to note that a slight correlation of increased weight loss in patients experiencing nausea has been reported [64,89], and that the presence of nausea (if tolerated by the patient) therefore paradoxically could be linked to a beneficial patient outcome.”
BackgroundMethodResultInfluentialGarber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057 · cited 1×
“This was significantly lower than in the comparator group (24%), which was treated with high doses of glimepiride [76].”
BackgroundVilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · cited 3×
“GLP-1 also delays gastric emptying and induces satiety, thus decreasing energy intake, which leads to weight loss [2].”
BackgroundSelf-citationPancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 4×
“, pancreatitis has been reported greater than sixfold more frequently as an adverse event for patients administered exenatide compared with other therapies for diabetes [52].”
BackgroundInfluentialZinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848 · cited 1×
“5 beats/min in the placebo group [85].”
Cited by
Pugliese, G., Penno, G., Natali, A., Barutta, F., Di Paolo, S., Reboldi, G., Gesualdo, L., & De Nicola, L. (2019) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.07.017 · Cited by 156
Nauck, M., Rizzo, M., Johnson, A., Bosch-Traberg, H., Madsen, J., & Cariou, B. (2016) · Diabetes Care · doi:10.2337/dc15-2479 · Cited by 143
GLP ‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond
Ryan, D., & Acosta, A. (2015) · Obesity · doi:10.1002/oby.21107 · Cited by 112
“This topic has been reviewed recently (118), and antibody formation and injection-site reactions are reportedly more frequent for the exendin-4-based compounds (for example, exenatide and lixisenatide), compared with liraglutide.”
BackgroundFayfman, M., Galindo, R. J., Rubin, D. J., Mize, D. L., Anzola, I., Urrutia, M. A., Ramos, C., Pasquel, F. J., Haw, J. S., Vellanki, P., et al. (2019) · Diabetes Care · doi:10.2337/dc18-1760 · Cited by 85
Metadata
- Authors
- Jespersen, M. J., Knop, F. K., & Christensen, M.
- Venue
- Expert Opinion on Drug Metabolism & Toxicology
- Publisher
- Informa Healthcare
- Published
- 2012-10-24
- Volume
- 9
- Issue
- 1
- Pages
- 17-29
- ISSN
- 1742-5255 (ISSN-L)
- 1744-7607
- OpenAlex
- W2117177423
- Cited by
- 57
- References
- 30
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations. https://app.cochat.ai/papers/10.1517/17425255.2013.731394
- The paper
- Jespersen, M. J., Knop, F. K., & Christensen, M. (2013). GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opinion on Drug Metabolism & Toxicology. https://doi.org/10.1517/17425255.2013.731394
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.